Tracers / [211At]At-astatobenzamide-N-3-hydroxypropylidene-3
[211At]At-astatobenzamide-N-3-hydroxypropylidene-3
Also written as [At-211]astatobenzamide-N-3-hydroxypropylidene-3; [At-211]astato-benzamide-N-3-hydroxypropylidene-3
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- radiohalogenated amidobisphosphonate
- Target / mechanism
- bone mineral (hydroxyapatite)-binding bisphosphonate PMID 10628558
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 10628558 1999 Nucl Med Biol |
Need this precursor?We can point you to suppliers for [211At]At-astatobenzamide-N-3-hydroxypropylidene-3, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.